Protective effects of fibronectin in galactosamine-induced liver failure in rats.
The effects of supplementation with fibronectin on liver damage and survival in rats with galactosamine-induced liver failure were studied. In rats with acute liver failure induced by a low dose of galactosamine, supplementation with purified plasma fibronectin at 3 hr after the administration of galactosamine provided significant increase of plasma fibronectin levels and augmentation of reticuloendothelial system function at 4 hr, significantly higher plasma fibronectin levels and significant protection of liver damage with shorter prothrombin times, lower AST and less histological damage at 48 hr as compared to control animals. Plasma fibronectin levels were inversely correlated with both plasma prothrombin times and AST. Fibronectin supplementation at 6 hr also resulted in the significant decrease of liver damage at 48 hr as evaluated histologically. When rats with liver failure, induced by a high dose of galactosamine, were supplemented with fibronectin at 3 hr, the survival rate was significantly higher than that of control rats. The results indicate that fibronectin supplementation in the early stages of acute liver failure could reduce liver damage and improve the survival of rats with galactosamine-induced liver failure.
D000208:Acute Disease; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000139:chemically induced / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005353:Fibronectins / Q000097:blood / Q000627:therapeutic use*; D005688:Galactosamine; D008297:Male; D012157:Mononuclear Phagocyte System / Q000187:drug effects; D011517:Prothrombin Time; D051381:Rats; D011919:Rats, Inbred Strains
D005353:Fibronectins; D005688:Galactosamine